Volume : 09, Issue : 10, October – 2022



Authors :

Naveena.B*, Melwinraj.A, Pratheesh Xavier.P, Narmatha.M, Thirupathi Kumaresan.P

Abstract :

In 1963, an expert committee of the World Health Organization defined cor-pulmonale as “hypertrophy of the right ventricle resulting from diseases affecting the function and/or structure of the lungs…,”but this pathological definition is in fact of limited value in clinical practice. Mild-to-moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival. Habitual lung conditions as well as conditions of the pulmonary vessels beget increased pulmonary vascular resistance. The most common beginning medium causing increased pulmonary blood pressure (pulmonary hypertension) is by pulmonary vasoconstriction, activation of coagulation pathway and annihilation of pulmonary arterial vessels. Pulmonary hypertension causes pressure load on the right ventricle and hence right ventricular blowup. Originally, there’s right ventricular hypertrophy, but as cardiac decompensation sets in and right heart failure ensues, dilatation of right ventricle occurs. In patients with COPD, clinical signs may be masked by lung hyperinflation. Most patients initially have dyspnea, which becomes more severe as right ventricular failure occurs. Chest pain may occur and be difficult to differentiate from angina pectoris. In patients with severe COPD, orthopnea, worsening right ventricular function, bloating and early satiety occurs. The goal of treatment is to control symptoms. It is important to treat medical problems that cause pulmonary hypertension, because they can lead to Cor- pulmonale. As per NICE (National Institute for Health and Care Excellence) guidelines, the treatment of Cor pulmonale is Long Term Oxygen Therapy.
Key words: Cor-pulmonale, Pulmonary hypertension, COPD, Oxygen, pulmonary arterial pressure

Cite This Article:

Please cite this article in Naveena.B et al, Comprehensive Assessment of Cor Pulmonale In COPD., Indo Am. J. P. Sci, 2022; 09(10).

Number of Downloads : 10


1. World Health Organization. Chronic cor pulmonale: report of an Expert Committee [meeting held in Geneva from 10 to 15 October 1960]. World Health Organization; 1961.
2. Fishman AP. Chronic cor pulmonale. American Review of Respiratory Disease. 1976 Oct;114(4):775-94.
3. Weitzenblum E. Chronic cor pulmonale. Heart. 2003 Feb 1;89(2):225-30.
4. Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic cor pulmonale in COPD. International journal of chronic obstructive pulmonary disease. 2007 Sep;2(3):273.
5. Wsphassociation.org. 2022 [cited 7 October 2022]. Available from: http://www.wsphassociation.org/wp-content/uploads/2019/04/Primary-Pulmonary-Hypertension-Evian-1998.pdf
6. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. European Respiratory Journal. 2008 Nov 1;32(5):1371-85.
7. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2005 Apr;2(1):20-2.
8. Mohan H. Textbook of pathology. Jaypee Brothers Medical Publishers; 2018 Nov 30.COR PULMONALE:418
9. MacNee W. Right ventricular function in cor pulmonale. Cardiology. 1988;75(Suppl. 1):30-40.
10. Matthay RA, Arroliga AC, Wiedemann HP, Schulman DS, Mahler DA. Right ventricular function at rest and during exercise in chronic obstructive pulmonary disease. Chest. 1992 May 1;101(5):255S-62S.
11. Hales CA. The site and mechanism of oxygen sensing for the pulmonary vessels. Chest. 1985 Oct 1;88(4):235S-40S.
12. Euler UV, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. ActaPhysiologicaScandinavica. 1946 Aug;12(4):301-20.
13. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation research. 2006 Sep 29;99(7):675-91.
14. Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. QJM: An International Journal of Medicine. 1988 Jan 1;66(1):65-85.
15. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax. 1988 Mar 1;43(3):183-9.
16. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992 Mar;170(2):109-24.
17. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, Barbera JA. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. European Respiratory Journal. 2002 Apr 1;19(4):632-8.
18. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. Journal of the American College of Cardiology. 2004 Jun 16;43(12S):S25-32.
19. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. New England Journal of Medicine. 1991 May 30;324(22):1539-47.
20. Lee JD, Taraseviciene-Stewart L, Keith R, Geraci MW, Voelkel NF. The expression of prostacyclin synthase is decreased in the small pulmonary arteries from patients with emphysema. Chest. 2005 Dec 1;128(6):575S.
21. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine. 1993 Jun 17;328(24):1732-9.
22. Spiropoulos K, Trakada G, Nikolaou E, Prodromakis E, Efremidis G, Pouli A, Koniavitou A. Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respiratory medicine. 2003 Aug 1;97(8):983-9.
23. Peinado VI, Barberà JA, Abate P, Ramírez J, Roca J, Santos S, Rodriguez-roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 1999 May 1;159(5):1605-11.
24. Walter RE, Wilk JB, Larson MG, Vasan RS, KeaneyJr JF, Lipinska I, O’Connor GT, Benjamin EJ. Systemic inflammation and COPD: the Framingham heart study. Chest. 2008 Jan 1;133(1):19-25.
25. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, Weitzenblum E. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009 Sep 1;136(3):678-87.
26. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, Oh IJ, Kim KS, Kim YC, Lim SC. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Journal of Korean medical science. 2010 Oct 1;25(10):1487-91.
27. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, Oh IJ, Kim KS, Kim YC, Lim SC. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Journal of Korean medical science. 2010 Oct 1;25(10):1487-91.
28. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C, COBH Group. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thrombosis and haemostasis. 1994;72(09):343-6.
29. Erelel M, Ece T, Arseven O. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respiratory medicine. 2002 Jul 1;96(7):515-8.
30. Rizkallah J, Man SP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009 Mar 1;135(3):786-93.
31. Fraisse F, HOLZAPFEL L, COULAND JM, SIMONNEAU G, BEDOCK B, FEISSEL M, HERBECQ P, PORDES R, POUSSEL JF, ROUX L, Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American journal of respiratory and critical care medicine. 2000 Apr 1;161(4):1109-14.
32. Keller CA, Osterloh J, Espiritu J, Naunheim KS, McDonald JW, Ramos RR. Histopathologic diagnosis made in lung tissue resected from patients with severe emphysema undergoing lung volume reduction surgery. Chest. 1997 Apr 1;111(4):941-7.
33. Nakamura A, Kasamatsu N, Hashizume I, Shirai T, Hanzawa S, Momiki S, Sasaki K, Kinoshita M, Okada O, Tatsumi K, Kuriyama T. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000;67(5):502-6.
34. Deem S, Swenson ER, Alberts MK, Hedges RG, Bishop MJ. Red-blood-cell augmentation of hypoxic pulmonary vasoconstriction: hematocrit dependence and the importance of nitric oxide. American journal of respiratory and critical care medicine. 1998 Apr 1;157(4):1181-6.
35. Azarov I, Huang KT, Basu S, Gladwin MT, Hogg N, Kim-Shapiro DB. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. Journal of Biological Chemistry. 2005 Nov 25;280(47):39024-32.
36. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Dartevelle P, Housset B, Hamon M, Weitzenblum E, Adnot S. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003 Oct 14;108(15):1839-44.
37. King SJ, Booyse FM, Lin PH, Traylor MA, Narkates AJ, Oparil SU. Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis. American Journal of Physiology-Cell Physiology. 1989 Jun 1;256(6):C1231-8.
38. Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2000 Oct 1;162(4):1235-8.
39. Tschernko EM, Gruber EM, Jaksch P, Jandrasits O, Jantsch U, Brack T, Lahrmann H, Klepetko W, Wanke T. Ventilatory mechanics and gas exchange during exercise before and after lung volume reduction surgery. American journal of respiratory and critical care medicine. 1998 Nov 1;158(5):1424-31.
40. Wright JL, Lawson L, Paré PD, Hooper RO, Peretz DI, Nelems JB, Schulzer M, Hogg JC. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. American Review of Respiratory Disease. 1983 Oct;128(4):702-7.
41. Butler J, Schrijen F, Henriquez A, Pow JM, Albert RK. Cause of the Raised Wedge Pressure on Exercise in Chronic Obstructive Pulmonary Disease1, 2. Am Rev Respir Dis. 1988;138:350-4.
42. Richens JM, Howard P. Oedema in corpulmonale. Clinical science (London, England: 1979). 1982 Mar 1;62(3):255-9.
43. Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. European journal of respiratory diseases. 1987 Nov 1;71(5):419-29.
44. Matthay RA, Berger HJ. Cardiovascular function in cor pulmonale. Clinics in Chest Medicine. 1983 May 1;4(2):269-95.
45. Chetty KG, Brown SE, Light RW. Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs. American Review of Respiratory Disease. 1982 Aug;126(2):338-41.
46. Restrepo CI, Tapson VF. Pulmonary hypertension and cor pulmonale. Textbook of cardiovascular medicine. 1998;2:647-65.
47. Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. European Respiratory Journal. 1995 Sep 1;8(9):1445-9.
48. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. European heart journal. 1991 Feb 1;12(2):103-11.
49. Foster Jr WL, Pratt PC, Roggli VL, Godwin JD, HalvorsenJr RA, Putman CE. Centrilobular emphysema: CT-pathologic correlation. Radiology. 1986 Apr;159(1):27-32.
50. Katz J, Whang J, Boxt LM, Barst RJ. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. Journal of the American College of Cardiology. 1993 May 1;21(6):1475-81.
51. Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studied by serial observations during recovery. Circulation Research. 1969 Jan;24(1):51-60.
52. Garrison DM, Pendela VS, .Yamamoto K, Burnett Jr JC, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996 Dec;28(6):988-94.
53. Memon J. Cor pulmonale. InStatPearls [Internet] 2021 Aug 11. StatPearls Publishing.
54. Nadel JA, Murray JF. Textbook of respiratory medicine. Saunders; 2000.
55. Bratel T, Ljungman S, Runold M, Stenvinkel P. Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. Respiratory medicine. 2003 Apr 1;97(4):308-16.
56. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest. 1994 May 1;105(5):1377-82.
57. Weitzenblum E. Chronic cor pulmonale. Heart. 2003 Feb 1;89(2):225-30.
58. GRIFFITH GC. Cor pulmonale: its diagnosis and management. Diseases of the Chest. 1956 Mar 1;29(3):258-65.
59. NG115 Managing Pulmonary Hypertension and Cor Pulmonale. NICEGuidance(December2018-lastupdated2019)
60. Wang Q, Guo YZ, Zhang YT, Xue JJ, Chen ZC, Cheng SY, Ou MD, Cheng KL, Zeng WJ. The effects and mechanism of atorvastatin on pulmonary hypertension due to left heart disease. PloS one. 2016 Jul 7;11(7):e0157171.
61. Kashif M. Khan1; Jayesh B. Patel2; Timothy J. Schaefer.Nifedipine. [Updated 2022 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
62. Mohammad Javad F, Seiyed Mohammad Ali G. Effects of pentoxifylline on oxygenation and exercise tolerance in patients with severe chronic obstructive pulmonary disease.
63. https://phassociation.org/patients/treatments/bosentan/#:~:text=Bosentan%20is%20an%20oral%20medication,slow%20progression%20of%20the%20disease.
64. Sim JY. Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology. 2010 Jan 1;58(1):4-14.
65. Wang P, Yang J, Yang Y, Ding Z. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pakistan Journal of Medical Sciences. 2017 Mar;33(2):260.
66. Authored by Dr Colin Tidy, Reviewed by Dr Hayley Willacy | Cor Pulmonale. Last edited 15 Aug 2022 | Meets Patient’s editorial guidelines.
67. Weitzenblum E, Chaouat A. Cor pulmonale. Chronic respiratory disease. 2009 Aug;6(3):177-85.